These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 18953491

  • 1. Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma.
    Chamberlain MC, Johnston S.
    J Neurooncol; 2009 Feb; 91(3):359-67. PubMed ID: 18953491
    [Abstract] [Full Text] [Related]

  • 2. Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma.
    Chamberlain MC, Johnston S.
    Cancer; 2009 Apr 15; 115(8):1734-43. PubMed ID: 19197992
    [Abstract] [Full Text] [Related]

  • 3. Salvage therapy with single agent bevacizumab for recurrent glioblastoma.
    Chamberlain MC, Johnston SK.
    J Neurooncol; 2010 Jan 15; 96(2):259-69. PubMed ID: 19593660
    [Abstract] [Full Text] [Related]

  • 4. Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma.
    Chamberlain MC, Wei-Tsao DD, Blumenthal DT, Glantz MJ.
    Cancer; 2008 May 01; 112(9):2038-45. PubMed ID: 18361434
    [Abstract] [Full Text] [Related]

  • 5. Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma.
    Chamberlain MC, Tsao-Wei DD, Groshen S.
    Cancer; 2006 Jan 01; 106(1):172-9. PubMed ID: 16323194
    [Abstract] [Full Text] [Related]

  • 6. CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.
    Chamberlain MC, Glantz MJ.
    J Neurooncol; 2008 Sep 01; 89(2):231-8. PubMed ID: 18480965
    [Abstract] [Full Text] [Related]

  • 7. Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
    Chamberlain MC, Kim BT.
    J Neurooncol; 2017 Jul 01; 133(3):561-569. PubMed ID: 28500559
    [Abstract] [Full Text] [Related]

  • 8. Temozolomide for recurrent low-grade spinal cord gliomas in adults.
    Chamberlain MC.
    Cancer; 2008 Sep 01; 113(5):1019-24. PubMed ID: 18615600
    [Abstract] [Full Text] [Related]

  • 9. Temozolomide for recurrent intracranial supratentorial platinum-refractory ependymoma.
    Chamberlain MC, Johnston SK.
    Cancer; 2009 Oct 15; 115(20):4775-82. PubMed ID: 19569246
    [Abstract] [Full Text] [Related]

  • 10. Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.
    Chamberlain MC.
    J Neurooncol; 2015 Apr 15; 122(2):329-38. PubMed ID: 25563816
    [Abstract] [Full Text] [Related]

  • 11. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
    Chamberlain MC, Tsao-Wei DD.
    Cancer; 2004 Mar 15; 100(6):1213-20. PubMed ID: 15022289
    [Abstract] [Full Text] [Related]

  • 12. Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.
    Chamberlain MC, Colman H, Kim BT, Raizer J.
    J Neurooncol; 2017 Feb 15; 131(3):507-516. PubMed ID: 28204914
    [Abstract] [Full Text] [Related]

  • 13. Salvage chemotherapy with CPT-11 for recurrent meningioma.
    Chamberlain MC, Tsao-Wei DD, Groshen S.
    J Neurooncol; 2006 Jul 15; 78(3):271-6. PubMed ID: 16628476
    [Abstract] [Full Text] [Related]

  • 14. Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors.
    Benesch M, Windelberg M, Sauseng W, Witt V, Fleischhack G, Lackner H, Gadner H, Bode U, Urban C.
    Ann Oncol; 2008 Apr 15; 19(4):807-13. PubMed ID: 18056650
    [Abstract] [Full Text] [Related]

  • 15. Bevacizumab for recurrent ependymoma.
    Green RM, Cloughesy TF, Stupp R, DeAngelis LM, Woyshner EA, Ney DE, Lassman AB.
    Neurology; 2009 Nov 17; 73(20):1677-80. PubMed ID: 19917990
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.
    Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey LE.
    Int J Radiat Oncol Biol Phys; 2009 Sep 01; 75(1):156-63. PubMed ID: 19167838
    [Abstract] [Full Text] [Related]

  • 17. Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
    Chamberlain MC.
    Expert Rev Neurother; 2012 Aug 01; 12(8):929-36. PubMed ID: 23002937
    [Abstract] [Full Text] [Related]

  • 18. Single-agent bevacizumab is an effective treatment in recurrent glioblastoma.
    Hacibekiroglu I, Kodaz H, Erdogan B, Turkmen E, Ozcelik M, Esenkaya A, Saygi HM, Uzunoglu S, Cicin I.
    Med Oncol; 2015 Feb 01; 32(2):460. PubMed ID: 25572814
    [Abstract] [Full Text] [Related]

  • 19. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.
    Narayana A, Kelly P, Golfinos J, Parker E, Johnson G, Knopp E, Zagzag D, Fischer I, Raza S, Medabalmi P, Eagan P, Gruber ML.
    J Neurosurg; 2009 Jan 01; 110(1):173-80. PubMed ID: 18834263
    [Abstract] [Full Text] [Related]

  • 20. The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.
    Strowd RE, Abuali I, Ye X, Lu Y, Grossman SA.
    J Neurooncol; 2016 Mar 01; 127(1):165-71. PubMed ID: 26729269
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.